Table 1.
Clinical trials and treatment conditions of study samples
| Trial | Group | Biopsy week | Peptide antigens | Adjuvant(s) | SSV vs RV | Treatment group | n |
| Mel48 | 1A/2A | 0 | None | None | -* | Normal skin control | 3 |
| 1B | 1 | None | IFA | - | IFA | 3 | |
| 1C | 3 | None | IFA | SSV | IFA | 4 | |
| 2B | 1 | MELITAC-12.1 | IFA | - | IFA + P | 5 | |
| 2C | 3 | MELITAC-12.1 | IFA | SSV | IFA + P | 4 | |
| Mel58 | 2B/2C | 1 | MELITAC-12.1 | IFA + pICLC | - | IFA + pICLC + P | 12 |
| Mel60 Part 1 |
A | 1 | LPV7 +tet | IFA | - | IFA + P | 4 |
| A | 3 | LPV7 +tet | IFA | RV | IFA + P | 3 | |
| E | 1 | LPV7 +tet | IFA + pICLC | - | IFA + pICLC + P | 6 | |
| E | 3 | LPV7 +tet | IFA + pICLC | RV | IFA + pICLC + P | 6 | |
| Mel60 Part 2 | E2 | 1 | LPV7 | IFA + pICLC | - | IFA + pICLC + P | 9 |
| E2 | 3 | LPV7 | IFA + pICLC | SSV | IFA + pICLC + P | 14 | |
| Mel63 | A | 1 | 6MHP | IFA | - | IFA + P | 3 |
| A | 3 | 6MHP | IFA | SSV | IFA + P | 3 | |
| C | 1 | 6MHP | IFA + pICLC | - | IFA + pICLC + P | 6 | |
| C | 3 | 6MHP | IFA + pICLC | SSV | IFA + pICLC + P | 5 |
*Rows not marked as SSV or RV are from weeks 0–1 so SSV and RV are not applicable.
IFA, incomplete Freund’s adjuvant; LPV7, long peptide melanoma vaccine; MELITAC-12.1, 12 melanoma peptide vaccine; 6MHP, 6 melanoma helper peptide vaccine; P, peptide; pICLC, polyICLC; RV, rotating site vaccination; SSV, same-site vaccination.